Timothy Sullivan

Chief Executive Officer Zeteo

Seminars

Wednesday 3rd February 2027
Integrating Formulation, Device, & Combination Product Strategy Early to Avoid Costly Late-Stage Development Changes
2:30 pm
  • Avoid costly reformulation, redevelopment, and regulatory delays by integrating formulation, device, and combination-product strategy from the earliest stages of development rather than treating them as separate workstreams
  • Understand how formulation characteristics, delivery route requirements, and device performance interact to influence product success, patient usability, manufacturability, and long-term commercial viability
  • Learn practical lessons from developing integrated liquid and powder-based intranasal products, highlighting common mistakes that lead to drug-device compatibility challenges and how to prevent them
Timothy Sullivan, Chief Executive Officer, Zeteo Biomedical